Eisai CoSTU:EII +0.24%74 Net Margin % is -1.58% as of Mar. 2026. GuruFocus rates STU:EII with a GF Score™ of 74/100 and a GF Value™ of €30.90 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Eisai Co ranks worse than 52.72% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Eisai Co's Net Income for the
three
months ended in Mar. 2026 was €-18 Mil. Eisai Co's Revenue for the
three
months ended in Mar. 2026 was €1,120 Mil. Therefore, Eisai Co's net margin for the quarter that ended in Mar. 2026 was -1.58%.
The historical rank and industry rank for Eisai Co's Net Margin % or its related term are showing as below:
STU:EII'
s Net Margin % Range Over the Past 10 Years
Min: 4.67 Med: 6.9 Max: 17.5
Current: 4.67
STU:EII's Net Margin % is ranked worse than 52.72% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs STU:EII: 4.67
Eisai Co (STU:EII) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Eisai Co Net Margin % Related Terms
Eisai Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Eisai Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Eisai Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (STU:EII) has a Net Margin % of -1.58% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Eisai Co and its competitors. Over the past decade, Eisai Co's Net Margin % has ranged from 4.67 to 17.50. According to the industry distribution chart, Eisai Co ranks #504 out of 956 companies in the Drug Manufacturers industry, placing it in the top 52.7%.
Is Eisai Co's Net Margin % too high?
Eisai Co's current Net Margin % is -1.58%. Over the past 10 years, this metric has ranged from a low of 4.67 to a high of 17.50. Based on the distribution chart, Eisai Co ranks #504 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #504 out of 956 companies for Net Margin %. This places Eisai Co in the lower half of its industry. The industry median Net Margin % is 5.56. Historically, Eisai Co's own Net Margin % has ranged from 4.67 to 17.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Net Margin % is -1.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (STU:EII) is currently considered Significantly Undervalued. The stock's GF Value™ is €30.90, compared to a current price of €21.11 — trading 31.7% below its estimated fair value. The current Net Margin % is -1.58%. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Eisai Co (STU:EII), the current Net Margin % is -1.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (STU:EII) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of €21.11 is trading 31.7% below its estimated GF Value™ of €30.90.
GuruFocus considers Eisai Co to be Significantly Undervalued.
Key valuation signals for STU:EII:
Net Margin %: -1.58%
GF Value™: €30.90 vs. price of €21.11 (31.7% below fair value)
No single metric tells the full story. See the STU:EII stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for STU:EII
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EII has been successfully added to your 
